o-Toluoyl Chloride CAS 933-88-0 Tolvaptan Intermediate Factory High Quality

Short Description:

Chemical Name: o-Toluoyl Chloride 

CAS: 933-88-0

Assay: ≥99.0%

Appearance: Colorless Clear Liquid

Intermediate of Tolvaptan (CAS 150683-30-0) for the treatment of Hyponatremia

High Quality, Commercial Production 

Inquiry: alvin@ruifuchem.com  

Product Detail

Related Products

Product Tags


Chemical Properties:

Chemical Name o-Toluoyl Chloride
Synonyms 2-Methylbenzoyl Chloride
CAS Number 933-88-0
CAT Number RF-PI396
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C8H7ClO
Molecular Weight 154.59
Melting Point 159.5-160.9℃
Boiling Point 88.0~90.0℃/12 mmHg (lit.)
Density  1.185 g/mL at 25℃ (lit.)
Refractive Index  n20/D 1.5549(lit.)
Water Solubility Reacts with Water
Brand Ruifu Chemical


Item Specifications
Appearance Colorless Clear Liquid
Assay ≥99.0%
Benzoyl Chloride ≤0.30%
M&P-Methyl Benzoyl Chloride ≤0.50%
O-Toluic Acid ≤0.50%
Other Unspecified Impurity ≤0.20%
Total Impurities ≤1.0%
Loss on Drying ≤0.50%
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, 25kg/Barrel or 180kg Plastic drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.





o-Toluoyl Chloride (CAS 933-88-0) is used as a pharmaceutical intermediate. o-Toluoyl Chloride is used in the synthesis if quinolinone compounds as SARS CoV 3CLpro inhibitors. Also used in the synthesis of benzooxaboroles as orally active anti-inflammatory agents. o-Toluoyl Chloride is the intermediate of Tolvaptan (CAS 150683-30-0) for the treatment of hyponatremia. Tolvaptan, also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Otsuka Pharmaceutical licensed tolvaptan under the trade name Samsca after the FDA approved the drug in May 2009.

  • Write your message here and send it to us